Clinical Trial

Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets

Study acronym: OCEAN-1
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The primary purpose is to evaluate the safety and efficacy of NAL ER for the treatment of chronic cough in participants with Idiopathic Pulmonary Fibrosis (IPF).
Protocol Amendment History 2 changes
critical Recruitment opened 2026-07-11
notable Trial sites expanded: 0 -> 5 locations 2026-07-11
Trial Details
NCT Number NCT07671911
Lead Sponsor Trevi Therapeutics
Conditions Idiopathic Pulmonary Fibrosis
Enrollment 306 participants
Start Date 2026-06-29
Primary Completion 2028-06 (estimated)
Study Completion 2028-07 (estimated)
Updated on ClinicalTrials.gov 2026-07-10